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Multiple-lentigines (ML)/LEOPARD (multiple lentigines, electrocardiographic-conduction abnormalities, ocular
hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) syn-
drome is an autosomal dominant condition—characterized by lentigines and cafe´ au lait spots, facial anomalies,
cardiac defects—that shares several clinical features with Noonan syndrome (NS). We screened nine patients
with ML/LEOPARD syndrome (including a mother-daughter pair) and two children with NS who had multiple
cafe´ au lait spots, for mutations in the NS gene, PTPN11, and found, in 10 of 11 patients, one of two new
missense mutations, in exon 7 or exon 12. Both mutations affect the PTPN11 phosphotyrosine phosphatase
domain, which is involved in !30% of the NS PTPN11 mutations. The study demonstrates that ML/LEOPARD
syndrome and NS are allelic disorders. The detected mutations suggest that distinct molecular and pathogenetic
mechanisms cause the peculiar cutaneous manifestations of the ML/LEOPARD-syndrome subtype of NS.
Multiple-lentigines (ML)/LEOPARD (multiple lentigi-
nes, electrocardiographic-conduction abnormalities, ocu-
lar hypertelorism, pulmonary stenosis, abnormal genita-
lia, retardation of growth, sensorineural deafness) syn-
drome (MIM *151100) is an autosomal dominant con-
dition characterized by ML, electrocardiographic-con-
duction abnormalities, ocular hypertelorism/obstructive
cardiomyopathy, pulmonary stenosis, abnormalities of
genitalia in males, retardation of growth, and deafness.
This group of characteristics was established as a distinct
disorder in 1969 (Gorlin et al. 1969). The diagnostic
criteria include ML plus two other recognized features
or a first-degree relative with ML plus three other fea-
tures in the patient (Voron et al. 1976). Several clinical
manifestations of ML/LEOPARD syndrome overlap
those of Noonan syndrome (NS [MIM #163950]), in-
cluding facial anomalies, distinct congenital heart de-
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fects, pectus deformities, hearing loss, and growth re-
tardation (Blienden et al. 1983; Gorlin et al. 1990;
Coppin and Temple 1997). Skin pigmentary changes
have been described in both disorders. NS often mani-
fests with pigmented nevi and cafe´ au lait spots, whereas
ML/LEOPARD syndrome manifests with cafe´ au lait
spots in early infancy and generalizedML after 5–6 years
of age (fig. 1) (Gorlin et al. 1990).
Mutations in PTPN11 (MIM *176876), a gene en-
coding the protein tyrosine phosphatase SHP-2 located at
chromosome 12q22-qter (Jamieson et al. 1994), have
been identified in a series of NS patients (Tartaglia et al.
2001). We screened for PTPN11 mutations in nine pa-
tients withML/LEOPARD syndrome, including amother-
daughter pair. We also screened for mutations two 3- and
5-year-old children with features of NS and multiple cafe´
au lait spots. Because of their early age, we suspected that
these two patients, having not yet developed lentigines,
could be regarded as representing examples of early-on-
set ML/LEOPARD syndrome. The criteria of Voron et al.
(1976) were used for the clinical diagnosis of ML/LEOP-
ARD syndrome. The present serieswas composedof seven
female patients and four male patients. Their ages ranged
between 3 and 39 years (mean age  SD 11.45
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Figure 1 Facial appearance of patient 2
years). Two patients (7 and 8) were related (i.e.,10.02
mother and daughter), and the remaining nine patients
were unrelated. Informed consent was obtained from all
patients enrolled in the study. Clinical findings in the pa-
tients are summarized in table 1.
Mutation screening of PTPN11 was performed by
SSCP analysis and direct sequencing of all 15 exons and
their flanking exon-intron junctions. Heterozygous se-
quence variations were identified in 10 of 11 patients
(table 1). A missense mutation (836ArG; Tyr279Cys)
in exon 7 was identified in three patients. Another mis-
sense mutation (1403CrT; Thr468Met) in exon 12 was
found in five unrelated patients and in the mother-
daughter pair (fig. 2). Samples from unaffected parents
were not available. The 836ArG and 1403CrT vari-
ations were not found in 100 random controls, nor were
they found in either the series of 87 patients with NS
that we studied (unpublished data) or the patients re-
ported by Tartaglia et al. (2001).
The recurrent mutations in exons 7 and 12, encoding
portions of the phosphotyrosine phosphatase (PTP) do-
main suggest that they are quite characteristically related
to the NS phenotype with skin manifestations, includ-
ing diffuse lentigines (fig. 3). Thr468Met in exon 12 ac-
counts for the 70% of mutations in the present series of
patients with ML/LEOPARD syndrome. No mutation
in exon 12 was reported in patients with NS, in whom
the N-terminal src-homology 2 (N-SH2) domain is af-
fected in two-thirds of cases (fig. 4). Only one-third of
NSmutations occur in the PTP domain, which represents
51% of the total protein. Only one NS mutation in exon
7 has previously been reported, in a different position
from the Tyr279Cys (Ile282Val) found in ML/LEOP-
ARD syndrome (fig. 4).
In the native protein, the amino acid Thr468 plays a
role that is essential to the catalytic activity. It is locat-
ed in the consensus sequence of the tyrosine-specific pro-
tein phosphatase’s active site (amino acids 457–469
[VHCSAGIGRTGTF]), which is necessary for Tyr-phos-
phatase activity. Moreover, in the native enzyme, Thr468
is involved in several hydrogen bonds toward the sol-
vent molecules, thus representing a stabilizing amino
acid for the protein. The methionine introduced in this
position may determine an overall change within the
protein-hydrogen networks, changing the intrinsic struc-
tural properties of the catalytic center. Both Tyr279 and
Thr468 amino acids are conserved in several related ty-
rosine phosphatases, suggesting that these residues play
a crucial role in the PTP-domain function.
Other syndromes display facial characteristics and
cardiac defects that may be superimposed with those of
NS, including ML/LEOPARD syndrome, cardiofacio-
cutaneous syndrome (CFCS [MIM 115150]), neurofibro-
matosis-Noonan syndrome (NFNS [MIM 601321]), and
Costello syndrome (MIM *218040). However, each of
them has some additional features, an observation that
fits the idea that they represent clinically distinct dis-
orders. Nevertheless, the tendency to group (or “lump,”
rather than “split”) them was acknowledged elsewhere
(Mendez and Opitz 1985; Noonan 1999). For example,
NS and CFCS have been considered, on the basis of the
analysis of an extended pedigree in which individuals
who presented with either condition coexisted, as dif-
ferent manifestations of a unique disorder (Legius et al.
1998). ML/LEOPARD syndrome and NS share facial
anomalies (Gorlin et al. 1990) and congenital heart de-
fects, including valvular pulmonary stenosis and hyper-
trophic obstructive cardiomyopathy (Coppin and Tem-
ple 1997; Marino et al. 1999). Interestingly, one of the
patients whom we studied had partial atrioventricular
canal, which occurs in ∼15% of children with NS (Ma-
rino et al. 1999). On the contrary, electrocardiographic-
conduction anomalies are characteristic of ML/LEOP-
ARD syndrome. Deafness not only may be present in
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Figure 2 SSCP and sequence analysis of the two identified mutations. Anomalous patterns of DNA SSCP in patients with ML/LEOPARD
syndrome are indicated by asterisks (*). a, Mutation 836ArG in exon 7. b, Mutation 1403CrT in exon 12.
Figure 3 PTPN11 protein structure and location of the two missense mutations reported. N-SH2 and C-SH2 are the N-terminal and C-
terminal tandemly arranged SH2 domains, followed by a protein PTP domain at the C-terminus, where the two mutational hotspots are localized.
Functional domains’ amino acid boundaries are indicated.
children with ML/LEOPARD syndrome but also may
manifest in patients of advanced age, possibly account-
ing for the normal hearing function in the present series
of pediatric patients.
Diffuse lentiginosis is a distinct characteristic of ML/
LEOPARD syndrome (fig. 1). Lentigines are rarely present
at birth and, classically, develop during childhood, in-
creasing in number until puberty and darkening with age.
Cafe´ au lait spots often herald the appearance of ML (fig.
1). Both cafe´ au lait spots and lentigines are also reported
in 10% of patients with NS (Allanson 1987). The exon
12 mutation, which seems to be related to the full-blown
phenotype of ML/LEOPARD syndrome, was also found
in two patients with NS that was associated with multi-
ple large cafe´ au lait spots. Both these children were !5
years old at the time of evaluation. Thus, it is not possible
to predict whether they will develop the ML phenotype
later in life or whether they will maintain the NS phe-
notype with prominent skin features. Watson syndrome
(MIM #193520)—characterized by valvular pulmonary
stenosis, short stature, mild mental retardation, and cafe´
au lait spots (Watson 1967)—also overlaps with NS,ML/
LEOPARD syndrome, and neurofibromatosis type 1
(NF1 [MIM *162200]). Mutations in the neurofibromin
Reports 393
Figure 4 Structure of PTPN11 protein representation with mu-
tated amino acids. Ca-traces of the N-SH2 (green), C-SH2 (clear
green), and PTP (red) domains are shown. Mutated residues are in-
dicated by thick lines. Most mutations (thick, white lines) in patients
with NS who have been described elsewhere (Tartaglia et al. 2001)
are located in the N-SH2 domain. The ML/LEOPARD mutations
(thick, cyan lines) are located in the PTP domain. This model was
made by use of the program Deep View Swiss-PdbViewer.
gene (NF1) have been reported in patients with Watson
syndrome (Tassabehji et al. 1993), confirming that this
disorder is allelic to NF1. However, genetic heterogeneity
cannot be excluded, since no linkage with NF1 was re-
ported in another family withWatson syndrome (Ahlbom
et al. 1995).
In the present series of patients with ML/LEOPARD
syndrome, a mutation in PTPN11 was found in all but
one patient, suggesting genetic heterogeneity. In patients
who had lentigines that were not related to NS, the di-
agnosis of NF1 should be considered, since a mutation
of the NF1 gene was found in a woman said to be af-
fected by ML/LEOPARD syndrome (Wu et al. 1996); it
should be noted, however, that the diagnosis of ML/
LEOPARD syndrome was doubtful, and the NF1 mis-
sense mutation was of uncertain pathological signifi-
cance. Therefore, molecular studies may be warranted,
to test other syndromes with ML (Pipkin and Pipkin
1950; Dociu et al. 1976; Carney et al. 1986; Schievink
et al. 1995) for PTPN11 mutations.
In conclusion, the present study demonstrates that
PTPN11 mutations cause ML/LEOPARD syndrome in
addition to the classical NS. The mutations detected in
the present series of patients suggest that specific molec-
ular and pathogenetic mechanisms are the cause of the
peculiar cutaneous manifestations of the ML/LEOPARD-
syndrome subtype of NS.
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